I’ve been invested in Cizzle Biotechnology Holdings for years. Unlike many of my investments, I haven’t spoken too much about it. Because until they could long-run patent, manufacture and sell their early-stage lung cancer test, the entire thesis lived in the land of theory, both in terms of financial and life-saving returns. I’m going to assume readers know nothing - so those of you familiar with the basics, bear with me.